- P-ISSN 1010-0695
- E-ISSN 2288-3339
- Apply for Authority
- P-ISSN1010-0695
- E-ISSN2288-3339
Article Detail
Home > Article Detail
A Review on Safety of Herbal Medicines for Doping
Journal of Korean Medicine / Journal of Korean Medicine, (P)1010-0695; (E)2288-3339
2019, v.40 no.3, pp.139-176
https://doi.org/10.13048/jkm.19032
&
(2019). A Review on Safety of Herbal Medicines for Doping. Journal of Korean Medicine, 40(3), 139-176, https://doi.org/10.13048/jkm.19032
- Downloaded
- Viewed
Abstract
Objectives: This study aims to review the herbal medicines containing substances banned by World Anti-Doping Agency(WADA), and to consider criteria for the using of herbal medicines. Methods: Using foreign(Pubmed, Cochrane, Embase, Google Scholar, WANFANG, CiNii) and domestic databases (NDSL, OASIS, RISS), we analyzed the content and pharmacokinetics of the prohibited substances in herbal medicines. Results: Herbal medicines containing the prohibited substances proposed in Korea, China, and Japan are Ephedrae Herba, Cannabis Semen, Strychni Semen, Strychni Ignatii Semen, Pinelliae Tuber, Rhizoma Pinelliae, Chelidonii Herba, Papaveris Fructus Deseminatus, Liriopis Tuber, Rehmanniae Radix Recens, Cistanchis Herba, Ponciri Fructus Immaturus, Aurantii Fructus Immaturus, Moschus, Testudinis Plastrum, Otariae Testis et Penis, and Hominis Placenta. Of these, when using Ephedrae Herba, Cannabis Semen, Strychni Semen, Moschus, Strychni Ignatii Semen, and Otariae Testis et Penis, caution is needed in relation to the doping test. Other herbal medicines are considered safe for the doping test. In addition, by analyzing data related to higenamine added to the WADA's prohibited list of doping since 2017, we don’t recommend using Nelumbinis Plumula. And in the case of the other herbal medicines containing higenamine, it is considered that care should be taken in doping test depending on the amount of usage. Conclusions: As a result of analyzing the herbal medicines which are in prohibited list about doping, we were able to know the criteria and precautions to use when prescribing the herbal medicines. Further research will be needed about common used herbal medicines and the amount of detection depending on extraction and boiling method.
- keywords
- WADA, doping, safety, herbal medicines
Reference
1
1. Verroken M. Drug use and abuse in sport. Baillieres Best Pract Res Clin Endocrinal Metab. 2000;14:1-23.
2
2. Kim JH. Sports-moral and ethical aspects. Seoul:Rainbowbooks. 2015:97-9.
3
3. Lee HS. Sports sociology. Seoul:Sungshin press. 2004:301.
4
4. Kim JR. A counter-strategy of Korea for anti-doping policy in world sports [dissertation]. Seoul: Hansung University; 2002.
5
5. Judkins C, Prock P. Supplements and inadvertent doping - how big is the risk to athletes. Med Sport Sci. 2012;59:143-52.
6
6. Kim JK, Chun YS, Kang SK, Cho HC. The use of herbal/traditional products supplementation and doping tests in elite athletes. Korean Journal of Sport Science. 2009;20(4):734-42.
7
7. Yun SJ, Je JJ, Lee H, Kim YJ, Lee HS. Anti-dopping of herbal medicine in 2015. J Sports Korean Med. 2015;15(1):1-9.
8
8. Kim JK, Kang SK, Jung HS, Chun YS, Trilk J, Jung SH. Dietary supplementation patterns of Korean olympic athletes participating in the Beijing 2008 summer olympic games. Int J Sport Nutr Exerc Metab. 2011 Apr;21(2):166-74.
9
9. Yun SJ. Anti-doping of herbal medicine in 2018. The Korean Medicine Times. 2018 Jul 2;2171:23 (col. 1).
10
10. World anti-doping agency(WADA) [Internet]. Montreal(Quebec): WADA 2018; c2018 [cited 2018 Oct 3]. Available from:https://www.wada-ama.org/.
11
11. Korea anti doping agent [Internet]. Seoul:KOREA ANTI-DOPING AGENCY; c2014[cited 2018 Oct 3]. Available from:https://www.kada-ad.or.kr/.
12
12. China anti-doping agency [Internet]. Beijing:CHINADA; c2015-2016 [cited 2018 Oct 3]. Available from: http://www.chinada.cn/.
13
13. CFDA [Internet]. Beijing: CFDA [cited 2018Oct 3]. Available from:http://eng.sfda.gov.cn/WS03/CL0755/.
14
14. Japan anti-doping agency(JADA) [Internet]. Tokyo: JAPAN Anti-Doping Agency; [cited 2018 Oct 3]. Available from:https://www.playtruejapan.org/.
15
15. JSPO [Internet]. Tokyo: Japan Sport Association;[cited 2018 Oct 3]. Available from:https://www.japan-sports.or.jp/.
16
16. Tokyo pharmaceutical association [Internet]. Tokyo: TOKYO PHARMACEUTICAL ASOCIATION; [cited 2018 Oct 3]. Available from: http://www.toyaku.or.jp/index.html.
17
17. UEFA [Internet]. Switzerland: UEFA; c1998–2018. UEFA competitions cases: July-december 2016; 2017 Apr 19 [cited 2018 Nov 24];[about 104 p.]. Available from:https://www.uefa.com/MultimediaFiles/Downlo ad/OfficialDocument/uefaorg/UEFACompDisC ases/02/45/96/63/2459663_DOWNLOAD.pdf.
18
18. Ministry of Food and Drug Safety [Internet]. Cheongju: Ministry of Food and Drug Safety;The Korean pharmacopoeia 11th edition; 2018Oct 14 [cited 2018 Nov 24]; [about 2554 p.]. Available from:http://drug.mfds.go.kr/html/menuLinkBody.jsp? p_menuId=0514.
19
19. Andraws R, Chawla P, Brown DL. Cardiovascular effects of ephedra alkaloids: A comprehensive review. Prog Cardiovasc Dis. 2005 Jan-Feb;47(4):217-25.
20
20. Herbal Pharmacology textbook compilation committee, editor. Herbal pharmacology. 4th ed. Seoul:Shinilbooks. 2015:202-7, 260-5, 348-64, 365-9, 733-5, 799-803, 877-80, 934-7.
21
21. Kim HC. Herbal medicine pharmacology. Seoul:Jipmoon. 2001:63-6, 180..
22
22. Rice J, Proctor K, Lopardo L, Evans S, Kasprzyk-Hordern B. Stereochemistry of ephedrine and its environmental significance:Exposure and effects directed approach. J Hazard Mater. 2018 Apr 15;348:39-46.
23
23. Soni MG, Carabin IG, Griffiths JC, Burdock GA. Safety of ephedra: Lessons learned. Toxicol Lett. 2004 Apr 15;150(1):97-110.
24
24. Maglione M, Miotto K, Iguchi M, Jungvig L, Morton SC, Shekelle PG. Psychiatric effects of ephedra use: An analysis of food and drug administration reports of adverse events. Am J Psychiatry. 2005 Jan;162(1):189-91.
25
25. Song YK, Lim HH. Clinical application of ma huang in the obesity treatment. Journal of Society of Korean Medicine for Obesity Research. 2007;7(1):1-7.
26
26. Astrup A, Toubro S. Thermogenic, metabolic, and cardiovascular responses to ephedrine and caffeine in man. Int J Obes Relat Metab Disord. 1993 Feb;17 Suppl 1:S41-3.
27
27. Wilkinson GR, Beckett AH. Absorption, metabolism, and excretion of the ephedrines in man. II. Pharmacokinetics. J Pharm Sci. 1968Nov;57(11):1933-8.
28
28. Haller CA, Jacob P 3rd. Benowitz NL. Pharmacology of ephedra alkaloids and caffeine after single-dose dietary supplement use. Clin Pharmacol Ther. 2002 Jun;71(6):421-32.
29
29. Pickup ME, May CS, Ssendagire R, Paterson JW. The pharmacokinetics of ephedrine after oral dosage in asthmatics receiving acute and chronic treatment. Br J Clin Pharmacol. 1976Feb;3(1):123-34.
30
30. Gurley BJ, Gardner SF, White LM, Wang PL. Ephedrine pharmacokinetics after the ingestion of nutritional supplements containing Ephedra sinica (ma huang). Ther Drug Monit. 1998Aug;20(4):439-45.
31
31. Chan KH, Pan RN, Hsu MC. Simultaneous quantification of six ephedrines in a Mahwang preparation and in urine by high‐performance liquid chromatography. Biomed Chromatogr. 2005 Jun;19(5):337-42.
32
32. Tseng YL, Shieh MH, Kuo FH. Metabolites of ephedrines in human urine after administration of a single therapeutic dose. Forensic Sci Int. 2006 Mar 10;157(2-3):149-55.
33
33. Kojima A, Nishitani Y, Sato M, Kageyama S, Dohi M, Okano M. Comparison of urine analysis and dried blood spot analysis for the detection of ephedrine and methylephedrine in doping control. Drug Test Anal. 2016 Feb;8(2):189-98.
34
34. White LM, Gardner SF, Gurley BJ, Marx MA, Wang PL, Estes M. Pharmacokinetics and cardiovascular effects of ma‐huang (Ephedra sinica) in normotensive adults. J Clin Pharmacol. 1997 Feb;37(2):116-22.
35
35. He F, Luo J, Chen F, Yu L. Human pharmacokinetics of ephedrine and pseudoephedrine in Mahuang Tang by GC-MS. Traditional Chinese Drug Research and Clinical Pharmacology. 2004 Sep;15(5):336-8,347.
36
36. Chan KH, Pan RN, Hsu MC, Hsu KF. Urinary elimination of ephedrines following administration of the traditional Chinese medicine preparation Kakkon-to. J Anal Toxicol. 2008 Nov-Dec;32(9):763-7.
37
37. Chan KH, Hsu MC, Chen FA, Hsu KF. Elimination of ephedrines in urine following administration of a Sho-seiryu-to preparation. J Anal Toxicol. 2009 Apr;33(3):162-6.
38
38. Jo YK. The study on anti-doping stability of ojeok-san by measuring ephedrine concentration of urine after taking ojeok-san [dissertation]. Seoul: KyungHee University; 2012.
39
39. Strano-Rossi S, Leone D, de la Torre X, Botre F. The relevance of the urinary concentration of ephedrines in anti-doping analysis:Determination of pseudoephedrine, cathine, and ephedrine after administration of over-the-counter medicaments. Ther Drug Monit. 2009 Aug;31(4):520-6.
40
40. Strano-Rossi S, Leone D, de la Torre X, Botre F. Analysis of stimulants in oral fluid and urine by gas chromatography-mass spectrometry II: Pseudophedrine. J Anal Toxicol. 2010May;34(4):210-5.
41
41. Barroso O, Goudreault D, Carbo Banus ML, Ayotte C, Mazzoni I, Boghosian T, et al. Determination of urinary concentrations of pseudoephedrine and cathine after therapeutic administration of pseudoephedrine-containing medications to healthy subjects: Implications for doping control analysis of these stimulants banned in sport. Drug Test Anal. 2012May;4(5):320-9.
42
42. Lee MK, Cheng BW, Che CT, Hsieh DP. Cytotoxicity assessment of Ma-huang (Ephedra)under different conditions of preparation. Toxicol Sci. 2000 Aug;56(2): 424-30.
43
43. Lee NR, Ha HK, Shin HK, Seo CS. Quantification, anti-inflammatory and antioxidant effects of mahwang-tang decoction according to the storage temperature and period. Kor J Pharmacogn. 2018;49(2):172-81.
44
44. Seo CS, Shin HK. Quantitative determination of twelve bioactive components in mahwang-tang, a traditional herbal prescription, using an LC-MS/MS. Yakhak Hoeji. 2016;60(6):320-6.
45
45. Song MY, Kim HJ, Lee MJ. The safety guidelines for use of ma-huang in obesity treatment. Journal of Korean Oriental Association for Study of Obesity. 2006;6(2):17-27.
46
46. Tyler VE. Herbs of choice: The therapeutic use of phytomedicinals. New York:Pharmaceutical procucts press. 1994:88-90.
47
47. Tong JY, Chao J, Dai YT, Fan ZQ, Wang DD, Qin XM, et al. Establish quality evaluation system for standard ephedrae herba decoction. Zhongguo Zhong Yao Za Zhi. 2017 Mar;42(5):823-9.
48
48. Aghdasi M, Bojnoordi MM, Mianabadi M, Nadaf M. Chemical components of the Ephedra major from Iran. Nat Prod Res. 2016;30(3):369-71.
49
49. Herbalism textbook compilation committee, editor. Herbalism. 2nd ed. Seoul:Young Lim Press. 2011:231-3, 289-90, 313-4, 392-5, 645-7, 677-8, 726.
50
50. Nahas GG. Marijuana in science and medicine. New York:Raven Press. 1984:25.
51
51. Bosy TZ, Cole KA. Consumption and quantitation of delta9-tetrahydrocannabinol in commercially available hemp seed oil products. J Anal Toxicol. 2000 Oct;24(7):562-6.
52
52. Cooper ZD, Haney M. Actions of delta-9-tetrahydrocannabinol in cannabis: Relation to use, abuse, dependence. Int Rev Psychiatry. 2009 Apr;21(2):104-12.
53
53. Katzung BG, Masters SB, Tevor AJ. Basic and clinical pharmacology. 12th ed. Seoul:Panmun. 2014:42, 587.
54
54. Ware MA, Jensen D, Barrette A, Vernec A, Derman W. Cannabis and the health and performance of the elite athlete. Clin J Sport Med. 2018 Sep;28(5):480-4.
55
55. Hilderbrand RL. Hemp & cannabidiol: What is a medicine? Mo Med. 2018 Jul-Aug;115(4):306-9.
56
56. Lowe RH, Abraham TT, Darwin WD, Herning R, Cadet JL, Huestis MA. Extended urinary Δ9-tetrahydrocannabinol excretion in chronic cannabis users precludes use as a biomarker of new drug exposure. Drug Alcohol Depend. 2009 Nov 1;105(1-2):24-32.
57
57. Ellis GM Jr, Mann MA, Judson BA, Schramm NT, Tashchian A. Excretion patterns of cannabinoid metabolites after last use in a group of chronic users. Clin Pharmacol Ther. 1985 Nov;38(5):572-8.
58
58. Campos DR, Yonamine M, de Moraes Moreau RL. Marijuana as doping in sports. Sports Med. 2003;33(6):395-9.
59
59. Brenneisen R, Meyer P, Chtioui H, Saugy M, Kamber M. Plasma and urine profiles of Δ9-tetrahydrocannabinol and its metabolites 11-hydroxy-Δ9-tetrahydrocannabinol and 11-nor -9-carboxy-Δ9-tetrahydrocannabinol after cannabis smoking by male volunteers to estimate recent consumption by athletes. Anal Bioanal Chem. 2010 Apr;396(7):2493-502.
60
60. Toennes SW, Ramaekers JG, Theunissen EL, Moeller MR, Kauert GF. Pharmacokinetic properties of Δ9-tetrahydrocannabinol in oral fluid of occasional and chronic users. J Anal Toxicol. 2010 May;34(4):216-21.
61
61. Kauert GF, Ramaekers JG, Schneider E, Moeller MR, Toennes SW. Pharmacokinetic properties of Δ9-tetrahydrocannabinol in serum and oral fluid. J Anal Toxicol. 2007Jun;31(5):288-93.
62
62. Hunault CC, Mensinga TT, de Vries I, Kelholt-Dijkman HH, Hoek J, Kruidenier M, et al. Delta-9-tetrahydrocannabinol (THC)serum concentrations and pharmacological effects in males after smoking a combination of tobacco and cannabis containing up to 69mg THC. Psychopharmacology (Berl). 2008Dec;201(2):171-81.
63
63. Hunault CC, van Eijkeren JC, Mensinga TT, de Vries I, Leenders ME, Meulenbelt J. Disposition of smoked cannabis with high Δ9-tetrahydrocannabinol content: A kinetic model. Toxicol Appl Pharmacol. 2010 Aug 1;246(3):148-53.
64
64. Zuurman L, Roy C, Schoemaker RC, Hazekamp A, den Hartigh J, Bender JC, et al. Effect of intrapulmonary tetrahydrocannabinol administration in humans. J Psychopharmacol. 2008 Sep;22(7):707-16.
65
65. Pacifici R, Pichini S, Pellegrini M, Tittarelli R, Pantano F, Mannocchi G, et al. Determination of cannabinoids in oral fluid and urine of “light cannabis” consumers: A pilot study. Clin Chem Lab Med. 2018 Dec 19;57(2):238-43.
66
66. Lemberger L, Tamarkin NR, Axelrod J, Kopin IJ. Delta-9-tetrahydrocannabinol: Metabolism and disposition in long-term marihuana smokers. Science. 1971 Jul 2;173(3991):72-4.
67
67. General information on herbal medicine [Internet]. Cheongju: National Institute of Food and Drug Safety Evaluation; c2009. Strychni Ignatii Semen; [cited 2018 Nov 18];[about 1 p.]. Available from:http://nifds.go.kr/herb/m_442/view.do;jsessioni d=u45mKSqBUljNUaMuzwQvB29NZjHdkwR gwxelQTMPSAjn5unI0MvSyh0AE3A8jt7c.nif ds_was2_servlet_engine1?code=KHP-N136&p age=22.
68
68. Gu ZP, Zhang SM, Wang CL, Lian WY, Xiao PG, Chen JM. Determation of strychnine and brucine in strychnos by HPLC. Yao Xue Xue Bao. 1997 Oct;32(10):791-4.
69
69. Duverneuil C, de la Grandmaison GL, de Mazancourt P, Alvarez JC. Liquid chromatography/photodiode array detection for determination of strychnine in blood: A fatal case report. Forensic Sci Int. 2004 Apr 20;141(1):17-21.
70
70. Emergency Response Safety and Health Database [Internet]. Atlanta: The National Institute for Occupational Safety and Health (NIOSH). [date unknown] - . STRYCHNINE :Biotoxin; [reviewed 2011 May 12; cited 2018Nov 29]; [about 12 screens]. Available from:https://www.cdc.gov/niosh/ershdb/emergencyre sponsecard_29750018.html.
71
71. Gossel TA, Bricker JD, editors. Principles of clinical toxicology. 3rd ed. New York:Raven Press. 1994:351.
72
72. Goodman LS, Gilman AG. Goodman and gilman's the pharmacological basis of therapeutics. New York:Macmillan Publishing & Co., Inc.. 1985:582-4.
73
73. Ellenhorn MJ, Schonwald S, Ordog G, Wasserberger J. Ellenhorn's medical toxicology: Diagnosis and treatment of human poisoning. 2nd ed. Baltimore, MD:Williams and Wilkins. 1997:1660.
74
74. Palatnick W, Meatherall R, Sitar D, Tenenbein M. Toxicokinetics of acute strychnine poisoning. J Toxicol Clin Toxicol. 1997;35(6):617-20.
75
75. Edmunds M, Sheehan TM, Van't Hoff W. Strychnine poisoning: Clinical and toxicological observations on a non-fatal case. J Toxicol Clin Toxicol. 1986;24(3):245-55.
76
76. Wood DM, Webster E, Martinez D, Dargan PI, Jones AL. Case report: Survival after deliberate strychnine self-poisoning, with toxicokinetic data. Crit Care. 2002 Oct;6(5):456-9.
77
77. Gupta RC, Patocka J. Handbook of toxicology of chemical warfare agents. London:Academic Press. 2009:199.
78
78. Van Eenoo P, Deventer K, Roels K, Delbeke FT. Quantitative LC–MS determination of strychnine in urine after ingestion of a strychnos nux-vomica preparation and its consequences in doping control. Forensic Sci Int. 2006 Dec 20;164(2-3):159-63.
79
79. Li J, Jiang Y. Rapid and sensitive determination of strychnine and brucine in human urine by capillary electrophoresis with field‐amplified sample stacking. Biomed Chromatogr. 2010Feb;24(2):186-94.
80
80. Kong HY, Zhou W, Guo PH, Sang ZC, Wu GN, Chen YJ, et al. Safety of individual medication of Ma Qian Zi (semen strychni)based upon assessment of therapeutic effects of Guo's therapy against moderate fluorosis of bone. J Tradit Chin Med. 2011 Dec;31(4):297-302.
81
81. Xu T, Zhang Y, Yu J. HPLC determination of strychnine in nux vomica powder. Heilongjiang Medicine Journal. 2012;25(1):11-2.
82
82. Tang HB, Zhang LJ, Li XL, Sun CF, Ma PJ. The experimental study of diferent solvent extracting total alkaloid from semen strychni. Guiding Journal of Traditional Chinese Medicine and Pharmacy. 2009;15(11):52-3.
83
83. Hu TG. Impact of traditional chinese medicine processing on physicochemical properties and efficacy of herbs. E-J Transl Med. 2015;2(4):115-6.
84
84. Xu WF, Zhang BG, Li M, Liu GH. Determination of ephedrine in rhizoma pinelliae, rhizoma typhonii flagelliformis and their processed products by HPLC. LISHIZHEN MEDICINE AND MATERIA MEDICA RESEARCH. 2007;18(4):884-5.
85
85. Qi HH, Wu JL, Xiang LY, Duan GL. Determination of ephedrine hydrochloride and pseudoephedrine hydrochloride in rhizoma pinelliae granules by HPLC. Science and Technology Innovation Herald. 2008 Aug 12;16:2 (col. 1).
86
86. Li ZH, Nie J, Ni KY, Du GH. Comparison of raizoma pinelliae from different producing areas. JOURNAL OF ANALYTICAL SCIENCE. 2005;21(4):393-5.
87
87. Zhu JJ, Guo ZY, Zhou Y, Yang J, Wang JZ, Zou K. Determination of alkaloids and the ephedrine in wild and tissue culture pinellia ternata(thunb) breit. Paper presented at:Seminar on the development and protection of Chinese herbal medicine and natural product resources; 2009 Sep 13; China Association for Pharmaceuticals and Medical Devices Technology Exchange(CPDE), Guilin, China.
88
88. Wu H, Tan X, Cai B, Ye D. Effect of ginger-processing on l-ephedrine contents in rhizoma pinelliae. Zhongguo Zhong Yao Za Zhi. 1996 Mar;21(3):157,158,190.
89
89. Jeong JG. A herbological study on the plants of papaveraceae in Korea. Kor J Herbol. 2016;31(5):63-9.
90
90. Choe S, Kim S, Lee C, Yang W, Park Y, Choi H, et al. Species identification of Papaver by metabolite profiling. Forensic Sci Int. 2011Sep 10;211(1-3):51-60.
91
91. Sárközi Á, Janicsak G, Kursinszki L, Kery A. Alkaloid composition of Chelidonium majus L. studied by different chromatographic techniques. Chromatographia. 2006;63(13):S81-6.
92
92. State Administration of Traditional Chinese Medicine, editor. Chinese herbal medicine. Vol. 3. Beijing:Shanghai Science and Technology Press. 1999:616-9.
93
93. Xinwenfeng Publishing Editorial Department, editor. New chinese medicine dictionary. Taipei:Xinwenfeng Publishing Co., Ltd.. 1981:605-6.
94
94. Fu Z, Fan X, Wang X, Gao X. Cistanches herba:An overview of its chemistry, pharmacology, and pharmacokinetics property. J Ethnopharmacol. 2018 Jun 12;219:233-47.
95
95. Koehler K, Thevis M, Schaenzer W. Metaanalysis:Effects of glycerol administration on plasma volume, haemoglobin, and haematocrit. Drug Test Anal. 2013 Nov-Dec;5(11-12):896-9.
96
96. Haaz S, Fontaine KR, Cutter G, Limdi N, Perumean‐Chaney S, Allison DB. Citrus aurantium and synephrine alkaloids in the treatment of overweight and obesity: An update. Obes Rev. 2006 Feb;7(1):79-88.
97
97. Stohs SJ, Preuss HG, Shara M. A review of the receptor-binding properties of p-synephrine as related to its pharmacological effects. Oxid Med Cell Longev. 2011;2011:482973.
98
98. Gutiérrez-Hellín J, Salinero JJ, Abían-Vicen J, Areces F, Lara B, Gallo C, et al. Acute consumption of p-synephrine does not enhance performance in sprint athletes. Appl Physiol Nutr Metab. 2016 Jan;41(1):63-9.
99
99. Kaats GR, Miller H, Preuss HG, Stohs SJ. A 60 day double-blind, placebo-controlled safety study involving Citrus aurantium (bitter orange) extract. Food Chem Toxicol. 2013May;55:358-62.
100
100. Stohs SJ, Preuss HG, Shara M. A review of the human clinical studies involving Citrus aurantium (bitter orange) extract and its primary protoalkaloid p-synephrine. Int J Med Sci. 2012;9(7):527-38.
101
101. Medana C, Calza P, Giancotti V, Dal Bello F, Aragno M, Baiocchi C. Study of the photocatalytic transformation of synephrine: A biogenic amine relevant in anti-doping analysis. Anal Bioanal Chem. 2013 Jan;405(2-3):1105-13.
102
102. Shara M, Stohs SJ, Smadi MM. Safety evaluation of p‐synephrine following 15 days of oral administration to healthy subjects: A clinical study. Phytother Res. 2018 Jan;32(1):125-31.
103
103. Ke X, Liu J, Chen C. HPLC fa ce ding cang zuo pen bi ye ji zuo shi yao cai zhong xin fu lin de han liang. Traditional Chinese Drug Research and Clinical Pharmacology. 2003;14(1):45-6.
104
104. Luo Z, Jing H. Content determination of synephrine in citrus auarntium L. by reversed phase ion-pair HPLC. China Pharmacy. 2006;17(19):1502-3.
105
105. Lu XF, Wang RJ, Peng G P, Deng YT. Determination of the content of synephrine in fructus aurantii immaturus by packed-column supercritical fluid chromatography. Liaoning Journal of Traditional Chinese Medicine. 2006; 33(2):222-3.
106
106. Zhao Y, Xie PS, Lu PH, Wang XH, Yang H. Determination of synephrine in Fructus aurantii immatus, Fructus aurantii, Pericarpium citri reticulatae viride and Pericarpium citri reticulatae. World Science and Technology/Modernization of Traditional Chinese Medicine and Materia Medica. 2006;8(4):64,67,106.
107
107. Nelson BC, Putzbach K, Sharpless KE, Sander LC. Mass spectrometric determination of the predominant adrenergic protoalkaloids in bitter orange (Citrus aurantium). J Agric Food Chem. 2007 Nov 28;55(24):9769-75.
108
108. Shawky E. Determination of synephrine and octopamine in bitter orange peel by HPTLC with densitometry. J Chromatogr Sci. 2014Sep;52(8):899-904.
109
109. Tanaka S, Sekiguchi M, Yamamoto A, Aizawa S, Sato K, Taga A, et al. Separation of synephrine enantiomers in citrus fruits by a reversed phase HPLC after chiral precolumn derivatization. Anal Sci [Internet]. 2018 Dec 14 [cited 2018 Dec 15]:[about 27 p.]. Available from: https://doi.org/10.2116/analsci.18P441doi:10.2116/analsci.18P441. PubMed PMID:30555107.
110
110. Wang J, He Y, Liu X, Yang Z, Yang W. Steroid profile and IRMS analysis of musk administration for doping control. Drug Test Anal. 2017 Nov;9(11-12):1779-87.
111
111. Thevis M, Schanzer W, Geyer H, Thieme D, Grosse J, Rautenberg C, et al. Traditional Chinese medicine and sports drug testing:Identification of natural steroid administration in doping control urine samples resulting from musk (pod) extracts. Br J Sports Med. 2013Jan;47(2):109-14.
112
112. He Y, Wang J, Liu X, Xu Y, He Z. Influences of musk administration on the doping test. Steroids. 2013 Nov;78(11):1047-52.
113
113. Zhang HL. Extracts from plastrum testudinis (PTD) promote proliferation of rat mesenchymal stem cell(MSCs) through BMP/ID pathway [dissertation]. Guangzhou: Guangzhou university of chinese medicine; 2009.
114
114. State Administration of Traditional Chinese Medicine, editor. Chinese herbal medicine. Vol. 9. Beijing:Shanghai Science and Technology Press. 1999:536-40, 593-5.
115
115. Granados J, Gillum TL, Christmas KM, Kuennen MR. Prohormone supplement 3b-hydroxy-5a-androst-1-en-17-one enhances resistance training gains but impairs user health. J Appl Physiol (1985). 2014 Mar 1;116(5):560-9.
116
116. SLAUNWHITE WR Jr, SANDBERG AA. Metabolism of 4-C14-testosterone in human subjects III. Fate of androsterone and etiocholanolone. J Clin Endocrinol Metab. 1958 Oct;18(10):1056-66.
117
117. Institute of pharmacopuncturology, editor. Pharmacopuncturology. Seoul:Elsevier Korea L.L.C.. 2008:200-7.
118
118. Lee SK, Lee JD, Koh HK. The study on the Hominis Placenta aqua-acupuncture solution. The Journal of Korea Acupuncture &Moxibustion Society. 2000;17(1):67-74.
119
119. NECA [Internet]. Seoul: NECA; c2017. Evaluation of medical technology regarding clinical effectiveness and safety of human placenta injection; 2010 Jul 19 [cited 2018Nov 24]; [about 203 p.]. Available from: https://www.neca.re.kr/lay1/program/S1T11C145/report/view.do?seq=22.
120
120. Melsmon [Internet]. Tokyo: Millennia Concepts (Official Website); c2015 [cited 2018 Nov 29]. Available from: http://melsmon.com/.
121
121. Tsukiyama M, Ueki T, Yasuda Y, Kikuchi H, Akaishi T, Okumura H, et al. Β2-adrenoceptor -mediated tracheal relaxation induced by higenamine from Nandina domestica Thunberg. Planta Med. 2009 Oct;75(13):1393-9.
122
122. Kashiwada Y, Aoshima A, Ikeshiro Y, Chen YP, Furukawa H, Itoigawa M, et al. Anti-HIV benzylisoquinoline alkaloids and flavonoids from the leaves of Nelumbo nucifera, and structure–activity correlations with related alkaloids. Bioorg Med Chem. 2005 Jan 17;13(2):443-8.
123
123. Chang YC, Chang FR, Khalil AT, Hsieh PW, Wu YC. Cytotoxic benzophenanthridine and benzylisoquinoline alkaloids from Argemone mexicana. Z Naturforsch C. 2003 Jul-Aug;58(7-8):521-6.
124
124. Kimura I, Chui LH, Fujitani K, Kikuchi T, Kimura M. Inotropic effects of (±)-higenamine and its chemically related components, ( )-Rcoclaurine and ( )-S-reticuline, contained in the traditional sino-japanese medicines “Bushi”and “Shin-i” in isolated guinea pig papillary muscle. Jpn J Pharmacol. 1989 May;50(1):75-8.
125
125. Bai G, Yang Y, Shi Q, Liu Z, Zhang Q, Zhu YY. Identification of higenamine in Radix Aconiti Lateralis Preparata as a beta2-adrenergic receptor agonist. Acta Pharmacol Sin. 2008 Oct;29(10):1187-94.
126
126. Kang YJ, Lee YS, Lee GW, Lee DH, Ryu JC, Yun-Choi HS, et al. Inhibition of activation of nuclear factor kappaB is responsible for inhibition of inducible nitric oxide synthase expression by higenamine, an active component of aconite root. J Pharmacol Exp Ther. 1999 Oct;291(1):314-20.
127
127. Praman S, Mulvany MJ, Williams DE, Andersen RJ, Jansakul C. Hypotensive and cardio-chronotropic constituents of Tinospora crispa and mechanisms of action on the cardiovascular system in anesthetized rats. J Ethnopharmacol. 2012 Mar 6;140(1):166-78.
128
128. Minami H, Dubouzet E, Iwasa K, Sato F. Functional analysis of norcoclaurine synthase in Coptis japonica. J Biol Chem. 2007 Mar 2;282(9):6274-82.
129
129. Zhang N, Lian Z, Peng X, Li Z, Zhu H. Applications of higenamine in pharmacology and medicine. J Ethnopharmacol. 2017 Jan 20;196:242-52.
130
130. Lee SR, Schriefer JM, Gunnels TA, Harvey IC, Bloomer RJ. Acute oral intake of a higenamine-based dietary supplement increases circulating free fatty acids and energy expenditure in human subjects. Lipids Health Dis. 2013 Oct 21;12:148.
131
131. Feng S, Jiang J, Hu P, Zhang JY, Liu T, Zhao Q, et al. A phase I study on pharmacokinetics and pharmacodynamics of higenamine in healthy chinese subjects. Acta Pharmacol Sin. 2012 Nov;33(11):1353-8.
132
132. Okano M, Sato M, Kageyama S. Determination of higenamine and coclaurine levels in human urine after the administration of a throat lozenge containing Nandina domestica fruit. Drug Test Anal. 2017 Nov;9(11-12):1788-93.
133
133. Du YR, Li F, Xu RY, Zhang Y, Ouyang M, Jing HL. Tolerability of higenamine hydrochloride in healthy volunteers. Chin J Clin Pharmacol. 2007;23(4):125-60.
134
134. Tian HF. Determination of higenamine by reversed phase high performance liquid chromatography with precolumn derivatization [dissertation]. Yanji city: Yanbian university;2011.
135
135. Tian HF, Yi T, Jing DR. Determination of higenamine in Nelumbo nucifera by HPLC with precolumn derivatization. Journal of Yanbian University(Natural Sciene). 2012;38(2):150-3.
136
136. Yang M, He S, Zhang D, Sun B, Wang Y. Study on determination of higenamine in chinese medicinal materials by LC-MS/MS. China measurement & test. 2018;44(3):61-5.
137
137. Kim SY, Geum DH, Lee MJ. A study on doping test of Bojungchisheup-tang. Korean J Ori Med. 1997;3(1):289-319.
138
138. Yoo HJ. Verification of efficacy as an ergogenic aid and safety in doping of Sibjeondaebo-tang [dissertation]. Seoul: Kyunghee university; 2014.
139
139. Lee JH. SK lim seok jin detection of doping...36 games ‘suspension’. The Kyunghyang Shinmun. 2017 Oct 28;Sect. A:24 (col. 6).
140
140. Kim HJ, Kwak BM, Ahn JH, Park JS. Simultaneous determination of synephrine and N-methyltyramine in orange fruit and juice from korean market by UPLC-FLD. Korean J Food Sci Technol. 2014;46(3):276-82.
141
141. Balasubramanian J, Maraicar KSH, Ananth DB, Vijayakumar N, Dhanalakishmi R. DHEA: The remedy for andropause. Indian J Med Healthcare. 2012 May;1(2):25-31.
142
142. Son YI. Verification and verification, seeking 100% safety : The placenta, which has been processed for 11 weeks at the greencross placenta injection plant in chungbuk eumseong, has been turned into a medicine. Weekly Donga. 2009 Oct 27;(708):36-9.
- Downloaded
- Viewed
- 0KCI Citations
- 0WOS Citations
Other articles from this issue
- Association between Korean Medicine Hospital Utilization and Cardiovascular Risks in Patients with Hypertension: a National Korean Cohort Study
- A Qualitative Study on Steering of Education Accreditation: With Case Study on Korean Medicine Education
- Effects of Curcuma longa Rhizoma on MIA-induced Osteoarthritis in Rat Model
- A study on the current status and development of the new health technology assessment of Korean medicine field
- A Study Assessing 2018 Gyenggi-do Korean medicine Support Project for Subfertility
- Analysis of Korean Medical status of Acute Bronchitis, Chronic Bronchitis and Allergic Rhinitis patients
- The Effect of Moxibustion Treatment for Cardiac Arrhythmia : A Systematic Review
- A Review on the Characteristics of Temperature Variation in Warm Needle
- A Review on Safety of Herbal Medicines for Doping
- A Rehabilitation protocol for Arthroscopic Bankart repair in Korean Medicine : A Case Report
- The Statistics Study on Patients visiting a Korean Medicine Hospital according to the Application of Chuna Therapy Health Insurance and Medical benefits
- The Effect of Korean Medical Treatments for Facial asymmetry Patients : Five Cases Report
- more
Recommanded Articles
This website recommended the use the Chrome browser for journal website.